Skip to content

ELASMOGEN

discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases

ELASMOGEN
  • about
    • the team
    • the board
    • investors
  • soloMER technology
    • discovery platform
    • product development options
  • pipeline
    • auto-Immune / anti-Inflammatory
    • oncology
    • NDURE programme
  • partners
    • licensing
    • partnerships and collaborations
  • news
    • press release
    • publications
    • events
  • contact
Press release

Press release

  • Home
  • News
  • Press release
  • Press release
  • Publications
  • Events

News archives

  • March 2023
  • September 2022
  • August 2022
  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • July 2016
  • March 2016

Dr Jane Dancer named as the new Chair of Elasmogen Ltd | 08.03.2023

8th March 2023 Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge Capital (BGF, Scottish National Investment Bank and Scottish Enterprise […]

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies | 16.09.2022

Date: 16th September 2022 Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen’s soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative […]

Research Scientist/Senior Research Scientist – Protein engineer and Protein chemist in Antibody drug discovery | 15.08.2022

Description Elasmogen Ltd is a multi-award-winning next generation therapeutic biologics company discovering and developing soloMERs™ for the treatment of oncology and autoimmune mediated inflammatory diseases. Currently located on the Foresterhill Health Campus, Aberdeen, and part of the city’s thriving biologics cluster, Elasmogen will be moving into the £40 million state-of-the-art Aberdeen life sciences BioHub also […]

BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen | 18.05.2022

Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen […]

Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses | 17.12.2021

MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new VNARs will not be immediately available as a treatment in people, but they […]

Researcher in Elasmogen Ltd receives prestigious fellowship worth £2 M to help establish him as a future leader of UK bioscience | 08.09.2021

Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune and anti-inflammation research efforts, and has received a £2 M research award of which £1.57 M is a grant […]

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners | 25.01.2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:  Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]

Elasmogen announces grants of 2 new VNAR and soloMER patent families | 09.12.2020

New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories.  These […]

Elasmogen wins two grants worth £374,000 | 08.07.2020

New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020:  Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology.  In April 2020 Elasmogen secured £143,000 from Scottish Government to use their drug discovery platform to accelerate […]

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain  binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]

ELASMOGEN Copyright 2023

Liberty Building | Foresterhill Health Campus | Aberdeen | AB25 2ZP

  • info@elasmogen.com
  • twitter
  • linkedin